The platform – opnME.com – provides access to molecules under two conditions, though the majority are available through a shopping cart system without having to enter into intellectual property discussions, the company said.
“For most of the compounds offered on the platform, Boehringer Ingelheim aims to unlock the full potential of compounds that will not be developed any further by the company, creating possibilities for independent and collaborative discovery as well as the identification of novel treatment approaches for patients,” Linda Ruckel, associate director, media and corporate reputation at Boehringer Ingelheim told Outsourcing-Pharma.com.
The company hopes to crowdsource project proposals for joint research and development of other selected molecules, Ruckel explained.
Researchers interested in these molecules are able to submit a research proposal, which if selected, will be developed further in collaboration with Boehringer Ingelheim scientists.
“Molecules will be selected on an ongoing basis from candidates that have been discontinued in the indication investigated by Boehringer Ingelheim, but could still show activity in other indications,” Ruckel said.
“Boehringer Ingelheim is looking forward to the ideas for investigation of the compounds and to contributing to bring more breakthrough medications to patients in need.”